Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.

The post Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug appeared first on MedCity News.